CL2020002051A1 - Formas de co-cristales de un análogo de novobiocina y prolina.- - Google Patents
Formas de co-cristales de un análogo de novobiocina y prolina.-Info
- Publication number
- CL2020002051A1 CL2020002051A1 CL2020002051A CL2020002051A CL2020002051A1 CL 2020002051 A1 CL2020002051 A1 CL 2020002051A1 CL 2020002051 A CL2020002051 A CL 2020002051A CL 2020002051 A CL2020002051 A CL 2020002051A CL 2020002051 A1 CL2020002051 A1 CL 2020002051A1
- Authority
- CL
- Chile
- Prior art keywords
- forms
- novobiocin
- crystals
- proline
- proline analog
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/207—Cyclohexane rings not substituted by nitrogen atoms, e.g. kasugamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
- C07H1/06—Separation; Purification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Emergency Medicine (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrane Compounds (AREA)
Abstract
Se divulgan formas de co-cristales de N-(2-(5-(((2R,3R,4S,5R)-3,4-dihidroxi-5-metoxi-6,6-dimetiltetra-hidro-2H-piran-2-il)oxi)-3'-fluoro-[1,1'-bifenil]-2-il)etil)-acetamida y L-prolina o D-prolina, sus composiciones farmacéuticas, procesos de fabricación y métodos de uso para tratar trastornos neurodegenerativos tales como la neuropatía periférica diabética.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862627570P | 2018-02-07 | 2018-02-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2020002051A1 true CL2020002051A1 (es) | 2021-02-19 |
Family
ID=65444361
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2020002051A CL2020002051A1 (es) | 2018-02-07 | 2020-08-07 | Formas de co-cristales de un análogo de novobiocina y prolina.- |
CL2022003784A CL2022003784A1 (es) | 2018-02-07 | 2022-12-27 | Formas co-cristalinas de un análogo de novobiocina y prolina |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2022003784A CL2022003784A1 (es) | 2018-02-07 | 2022-12-27 | Formas co-cristalinas de un análogo de novobiocina y prolina |
Country Status (18)
Country | Link |
---|---|
US (3) | US10717755B2 (es) |
EP (1) | EP3749675A1 (es) |
JP (2) | JP2021512910A (es) |
KR (1) | KR20200141985A (es) |
CN (1) | CN112020506A (es) |
AR (1) | AR114245A1 (es) |
AU (2) | AU2019217821B2 (es) |
BR (1) | BR112020016205A2 (es) |
CA (2) | CA3090646C (es) |
CL (2) | CL2020002051A1 (es) |
CO (1) | CO2020009761A2 (es) |
EA (1) | EA202091885A1 (es) |
IL (1) | IL276583A (es) |
MX (2) | MX2020008326A (es) |
PE (1) | PE20211446A1 (es) |
SG (1) | SG11202007530XA (es) |
TW (2) | TW202323267A (es) |
WO (1) | WO2019156907A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2020008326A (es) | 2018-02-07 | 2020-09-28 | Reata Pharmaceuticals Inc | Formas de co-cristales de un analogo de novobiocina y prolina. |
CN115181146A (zh) * | 2021-04-02 | 2022-10-14 | 浙江普洛家园药业有限公司 | 一种新生霉素的提取工艺 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9029369B2 (en) * | 2010-09-23 | 2015-05-12 | Nuformix Limited | Aprepitant L-proline composition and cocrystal |
US9035044B2 (en) * | 2011-05-09 | 2015-05-19 | Janssen Pharmaceutica Nv | L-proline and citric acid co-crystals of (2S, 3R, 4R, 5S,6R)-2-(3-((5-(4-fluorophenyl)thiopen-2-yl)methyl)4-methylphenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol |
US9532993B2 (en) * | 2011-11-25 | 2017-01-03 | Nuformix Limited | Aprepitant L-proline solvates—compositions and cocrystals |
EP2602249B1 (en) * | 2011-12-06 | 2015-08-12 | F.I.S. Fabbrica Italiana Sintetici S.p.A. | Synthesis of rosuvastatin by means of co-crystals |
WO2013119985A1 (en) * | 2012-02-09 | 2013-08-15 | University Of Kansas | C-terminal hsp90 inhibitors |
ES2671478T3 (es) * | 2012-08-31 | 2018-06-06 | Novartis Ag | Derivados de 2'-etinil nucleósidos para el tratamiento de infecciones virales |
TW201512201A (zh) * | 2013-03-14 | 2015-04-01 | Forum Pharmaceuticals Inc | 化合物的多晶型及鹽類 |
SG10201811574YA (en) * | 2014-06-24 | 2019-01-30 | Univ Kansas | Biphenyl amides with modified ether groups as hsp90 inhibitors and hsp70 inducers |
CA2961819C (en) * | 2014-09-30 | 2022-11-08 | Jiangsu Hengrui Medicine Co., Ltd. | L-proline compound of sodium-glucose cotransporter 2 inhibitor, and monohydrate and crystal of l-proline compound |
MX2020008326A (es) | 2018-02-07 | 2020-09-28 | Reata Pharmaceuticals Inc | Formas de co-cristales de un analogo de novobiocina y prolina. |
-
2019
- 2019-02-01 MX MX2020008326A patent/MX2020008326A/es unknown
- 2019-02-01 CA CA3090646A patent/CA3090646C/en active Active
- 2019-02-01 EP EP19705879.5A patent/EP3749675A1/en active Pending
- 2019-02-01 TW TW112106332A patent/TW202323267A/zh unknown
- 2019-02-01 BR BR112020016205-1A patent/BR112020016205A2/pt unknown
- 2019-02-01 TW TW108104336A patent/TWI797249B/zh active
- 2019-02-01 KR KR1020207025571A patent/KR20200141985A/ko not_active Application Discontinuation
- 2019-02-01 US US16/265,256 patent/US10717755B2/en active Active
- 2019-02-01 CN CN201980011980.6A patent/CN112020506A/zh active Pending
- 2019-02-01 AU AU2019217821A patent/AU2019217821B2/en active Active
- 2019-02-01 CA CA3226385A patent/CA3226385A1/en active Pending
- 2019-02-01 JP JP2020542665A patent/JP2021512910A/ja active Pending
- 2019-02-01 EA EA202091885A patent/EA202091885A1/ru unknown
- 2019-02-01 PE PE2020001199A patent/PE20211446A1/es unknown
- 2019-02-01 WO PCT/US2019/016304 patent/WO2019156907A1/en unknown
- 2019-02-01 SG SG11202007530XA patent/SG11202007530XA/en unknown
- 2019-02-05 AR ARP190100277A patent/AR114245A1/es unknown
-
2020
- 2020-06-05 US US16/894,461 patent/US11401294B2/en active Active
- 2020-08-06 CO CONC2020/0009761A patent/CO2020009761A2/es unknown
- 2020-08-06 MX MX2022012856A patent/MX2022012856A/es unknown
- 2020-08-07 CL CL2020002051A patent/CL2020002051A1/es unknown
- 2020-08-09 IL IL276583A patent/IL276583A/en unknown
-
2022
- 2022-12-05 AU AU2022283638A patent/AU2022283638A1/en active Pending
- 2022-12-27 CL CL2022003784A patent/CL2022003784A1/es unknown
-
2023
- 2023-02-13 US US18/168,495 patent/US20240043465A1/en active Pending
- 2023-10-05 JP JP2023173340A patent/JP2024001167A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
PE20211446A1 (es) | 2021-08-05 |
IL276583A (en) | 2020-09-30 |
JP2024001167A (ja) | 2024-01-09 |
CN112020506A (zh) | 2020-12-01 |
SG11202007530XA (en) | 2020-09-29 |
CA3090646C (en) | 2024-02-27 |
AU2019217821A1 (en) | 2020-09-24 |
EP3749675A1 (en) | 2020-12-16 |
US20240043465A1 (en) | 2024-02-08 |
AU2022283638A1 (en) | 2023-02-02 |
TW201945381A (zh) | 2019-12-01 |
US20200347088A1 (en) | 2020-11-05 |
US10717755B2 (en) | 2020-07-21 |
TWI797249B (zh) | 2023-04-01 |
JP2021512910A (ja) | 2021-05-20 |
MX2020008326A (es) | 2020-09-28 |
MX2022012856A (es) | 2022-11-30 |
AU2019217821B2 (en) | 2022-09-08 |
CL2022003784A1 (es) | 2023-06-09 |
WO2019156907A1 (en) | 2019-08-15 |
CA3226385A1 (en) | 2019-08-15 |
US20190241599A1 (en) | 2019-08-08 |
US11401294B2 (en) | 2022-08-02 |
BR112020016205A2 (pt) | 2020-12-15 |
KR20200141985A (ko) | 2020-12-21 |
TW202323267A (zh) | 2023-06-16 |
CO2020009761A2 (es) | 2020-10-30 |
CA3090646A1 (en) | 2019-08-15 |
EA202091885A1 (ru) | 2021-01-15 |
AR114245A1 (es) | 2020-08-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2022003784A1 (es) | Formas co-cristalinas de un análogo de novobiocina y prolina | |
ECSP19053616A (es) | N-[4-fluoro-5-[[(2s,4s)-2-metil-4-[(5-metil-1,2,4-oxadiazol-3-il)metoxi]-1-piperidil]metil]tiazol-2-il]acetamida como inhibidor de oga | |
DOP2022000278A (es) | Inhibidores de cisteína proteasas y sus métodos de uso | |
CO2020003432A2 (es) | Molécula de unión al antígeno multiespecífica que tiene actividad de sustitución de la función de cofactor del factor viii de coagulación de sangre (fviii) y formulación farmacéutica que contiene tal molécula como ingrediente activo | |
CL2018002516A1 (es) | Inhibidores de mcl-1 indólicos sustituidos. | |
CR20130580A (es) | Spiro-[1,3]-oxacinas y spiro-[1,4]-oxacepinas como inhibidores de bace1 y/o bace2 | |
EA201391786A1 (ru) | Галоген-алкил-1,3-оксазины в качестве ингибиторов bace1 и/или bace2 | |
CR9485A (es) | Modulators of indoleamine 2,3-dioxygenase and methods of using the same | |
EA201001371A1 (ru) | Конденсированные пиримидиноновые соединения как модуляторы trpv3 | |
CL2021002959A1 (es) | Nuevas formas sólidas de ácido (2s,3s,4s,5r,6s)-3,4,5-trihidroxi-6-(((4ar,10ar)-7- hidroxi-1-propil-1,2,3,4,4a,5,10,10a- octahidrobenzo[g]quinolin-6-il)oxi)tetrahidro2h-piran-2-carboxílico. | |
CL2013001073A1 (es) | Compuestos derivados de 6-amino-nicotinamidas sustituidas, como moduladores de kcnq2/3; composicion farmaceutica que los comprende, util para el tratamiento y/o profilaxis de trastornos y/o enfermedades seleccionadas de dolor, epilepsia, ansiedad, enfermedades cognitivas, entre otras. | |
CL2008002268A1 (es) | Compuestos derivados de amidas, moduladores del receptor taar1; proceso de obtencion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como depresion, ansiedad, estres, entre otros. | |
CL2018002367A1 (es) | Compuestos de bifenil amidas con grupos éteres modificados derivados de n-((2-(ciclohexiloxi o 2h-piran-2-iloxi)-3’-fluoro-[1,1’-bifenil]-2-il)-etil)-acetamida y 2-oxo-2h-cromen-3il-acetamida sustituidos; composiciones farmacológicas; inhibidores de hsp90 e inductores de hsp70, útiles para tratar trastornos neurológicos, asociados a las complicaciones de la diabetes, tales como neuropatía, nefropatía, retinopatía y vasculopatía. modificados como inhibidores de hsp90 e inductores de hsp70(div n° 3276-16) | |
CL2007003223A1 (es) | Compuestos derivados de piperidinil 4-arilsulfonamidas n-sustituidas, que actuan como moduladores de la proteina sfrp-1; proceso para preparar los compuestos; co mposicion farmaceutica que comprende a dichos copmpuestos y uso de los compuestos para preparar medicamentos para el tratamiento de enfermedades. | |
BR112019025230A2 (pt) | Anéis 5-5 fundidos como inibidores de c5a | |
EA201001586A1 (ru) | Соединения и композиции в качестве ингибиторов itpkb | |
NZ629778A (en) | C-terminal hsp90 inhibitors | |
BR112022021976A2 (pt) | Composto, e, composição farmacêutica compreendendo um composto | |
CL2012000097A1 (es) | Compuestos derivados de 3-fenoximetilpirrolidina, inhibidores de la recaptacion de serotonina-norepinefrina; procedimiento de preparacion; compuestos intermediarios; composicion farmaceutica que lo comprende; y su uso en el tratamiento de trastornos del dolor, depresion, entre otros. | |
NZ766972A (en) | Compounds having s1p5 receptor agonistic activity | |
CL2009001282A1 (es) | Compuestos derivados de pirrolidin amidas sustituidas, moduladores del receptor de histamina h3; composicion farmaceutica que los contiene; y su uso para el tratamiento de enfermedades tales como demencia, alzheimer, disfuncion cognitiva, trastorno de la memoria, trastorno de aprendizaje, deficit atencional, entre otras. | |
CL2020001461A1 (es) | Inhibidores de dopamina–b–hidroxilasa. | |
CL2008003780A1 (es) | Compuestos derivados de azetidinas; procedimiento de preparacion; compuestos intermediarios; composicion farmaceutica; y uso para el tratamiento o la prevencion de trastornos psiquiatricos, dependencia o deshabituacion a una sustancia, trastornos cognitivos, enfermedades neurodegenerativas, entre otras. | |
AR061890A1 (es) | Sal xinafoato del etil ester de la 1-[[5-(1s)-aminoetil)-2-[8-metoxi-2(trifluorometil)-5-quinolil]-4-oxazolil]carbonil]-(4r)-[(ciclopropil-carbonil)amino]-l-prolina. | |
CR20170426A (es) | Inhibidores de bace 1 |